Flagship Pioneering Appoints Rahul Kakkar as CEO-Partner and CEO of Quotient Therapeutics
Flagship Pioneering and Quotient Therapeutics have appointed Rahul Kakkar, M.D. as CEO-Partner and Chief Executive Officer. Dr. Kakkar brings nearly 20 years of experience in biotech entrepreneurship and medicine, previously serving as CEO of Tome Biosciences and Pandion Therapeutics, which was acquired by Merck for $1.85 billion.
Jake Rubens, Quotient's co-founder and former CEO, will transition to a board director role after successfully establishing the company's first industrial platform for discovering drug targets through somatic genomics and securing a collaboration with Pfizer in cardiovascular and renal diseases.
Dr. Kakkar, who continues to practice at Brigham and Women's Hospital and lecture at Harvard Medical School, will lead Quotient's efforts in advancing its pipeline and platform technology. The company's focus on somatic genomics aims to discover novel drug targets and create first-in-class medicines for various diseases.
Flagship Pioneering e Quotient Therapeutics hanno nominato Rahul Kakkar, M.D. come CEO-Partner e Amministratore Delegato. Il dottor Kakkar porta con sé quasi 20 anni di esperienza nell'imprenditoria biotecnologica e nella medicina, avendo precedentemente ricoperto il ruolo di CEO presso Tome Biosciences e Pandion Therapeutics, quest'ultima acquisita da Merck per 1,85 miliardi di dollari.
Jake Rubens, cofondatore e ex CEO di Quotient, passerà a un ruolo di direttore nel consiglio di amministrazione dopo aver fondato con successo la prima piattaforma industriale dell'azienda per la scoperta di target farmacologici attraverso la genomica somatica e aver siglato una collaborazione con Pfizer nelle malattie cardiovascolari e renali.
Il dottor Kakkar, che continua a esercitare presso il Brigham and Women's Hospital e a tenere lezioni alla Harvard Medical School, guiderà gli sforzi di Quotient nel potenziare la pipeline e la tecnologia della piattaforma. L'azienda si concentra sulla genomica somatica per scoprire nuovi target farmacologici e sviluppare farmaci innovativi di prima classe per diverse patologie.
Flagship Pioneering y Quotient Therapeutics han nombrado a Rahul Kakkar, M.D. como CEO-Socio y Director Ejecutivo. El Dr. Kakkar aporta casi 20 años de experiencia en emprendimiento biotecnológico y medicina, habiendo sido anteriormente CEO de Tome Biosciences y Pandion Therapeutics, esta última adquirida por Merck por 1.850 millones de dólares.
Jake Rubens, cofundador y ex CEO de Quotient, pasará a un rol de director en la junta tras establecer con éxito la primera plataforma industrial de la compañía para descubrir objetivos terapéuticos mediante genómica somática y asegurar una colaboración con Pfizer en enfermedades cardiovasculares y renales.
El Dr. Kakkar, que continúa ejerciendo en el Brigham and Women's Hospital y dando clases en la Harvard Medical School, liderará los esfuerzos de Quotient para avanzar en su cartera de proyectos y tecnología de plataforma. La empresa se enfoca en la genómica somática para descubrir nuevos objetivos terapéuticos y crear medicamentos innovadores de primera clase para diversas enfermedades.
Flagship Pioneering와 Quotient Therapeutics는 Rahul Kakkar, M.D.를 CEO-파트너 겸 최고경영자(CEO)로 임명했습니다. 카카 박사는 생명공학 기업가 정신과 의학 분야에서 거의 20년의 경력을 보유하고 있으며, 이전에는 Tome Biosciences와 Pandion Therapeutics의 CEO를 역임했으며, Pandion Therapeutics는 머크에 18억 5천만 달러에 인수되었습니다.
Quotient의 공동 창립자이자 전 CEO인 Jake Rubens는 체세포 유전체학을 통한 약물 표적 발견을 위한 회사 최초의 산업 플랫폼을 성공적으로 구축하고, 심혈관 및 신장 질환 분야에서 화이자와의 협력을 확보한 후 이사회 이사로 전환할 예정입니다.
카카 박사는 브리검 여성 병원에서 진료를 계속하며 하버드 의과대학에서 강의도 진행하고 있으며, Quotient의 파이프라인 및 플랫폼 기술 개발을 이끌 예정입니다. 회사는 체세포 유전체학에 중점을 두어 새로운 약물 표적을 발견하고 다양한 질병에 대해 선도적인 혁신 의약품을 개발하는 것을 목표로 하고 있습니다.
Flagship Pioneering et Quotient Therapeutics ont nommé Rahul Kakkar, M.D. en tant que CEO-Associé et Directeur Général. Le Dr Kakkar apporte près de 20 ans d'expérience en entrepreneuriat biotechnologique et en médecine, ayant précédemment occupé le poste de CEO chez Tome Biosciences et Pandion Therapeutics, cette dernière ayant été rachetée par Merck pour 1,85 milliard de dollars.
Jake Rubens, cofondateur et ancien CEO de Quotient, passera à un rôle de membre du conseil d'administration après avoir établi avec succès la première plateforme industrielle de l'entreprise pour la découverte de cibles médicamenteuses via la génomique somatique et obtenu une collaboration avec Pfizer dans les maladies cardiovasculaires et rénales.
Le Dr Kakkar, qui continue de pratiquer au Brigham and Women's Hospital et d'enseigner à la Harvard Medical School, dirigera les efforts de Quotient pour faire avancer son pipeline et sa technologie de plateforme. L'entreprise se concentre sur la génomique somatique afin de découvrir de nouvelles cibles médicamenteuses et de créer des médicaments de première classe pour diverses maladies.
Flagship Pioneering und Quotient Therapeutics haben Rahul Kakkar, M.D. zum CEO-Partner und Chief Executive Officer ernannt. Dr. Kakkar bringt nahezu 20 Jahre Erfahrung in der Biotech-Unternehmerschaft und Medizin mit und war zuvor CEO von Tome Biosciences und Pandion Therapeutics, das von Merck für 1,85 Milliarden US-Dollar übernommen wurde.
Jake Rubens, Mitbegründer und ehemaliger CEO von Quotient, wird nach erfolgreicher Etablierung der ersten industriellen Plattform des Unternehmens zur Entdeckung von Arzneimittelzielen mittels somatischer Genomik und dem Abschluss einer Zusammenarbeit mit Pfizer im Bereich Herz-Kreislauf- und Nierenerkrankungen in den Vorstand wechseln.
Dr. Kakkar, der weiterhin am Brigham and Women's Hospital praktiziert und an der Harvard Medical School lehrt, wird die Bemühungen von Quotient leiten, die Pipeline und Plattformentwicklung voranzutreiben. Das Unternehmen konzentriert sich auf somatische Genomik, um neuartige Arzneimittelziele zu entdecken und erstklassige Medikamente für verschiedene Krankheiten zu entwickeln.
- New CEO Rahul Kakkar has proven track record of successful exits - led Pandion Therapeutics to $1.85B Merck acquisition
- Previous leadership success includes Corvidia Therapeutics' $2.1B acquisition by Novo Nordisk
- Existing collaboration agreement with Pfizer in cardiovascular and renal diseases
- Company has established research presence in both UK and US markets
- Platform already validated and begun drug discovery across multiple diseases
- None.
Dr. Kakkar is a biotech entrepreneur and physician-scientist with nearly 20 years of professional experience founding and building biotechnology companies and practicing medicine. Previously, he served as President and CEO of Tome Biosciences, a genome engineering biotechnology platform company. Prior to Tome, Dr. Kakkar was CEO at Pandion Therapeutics, a biologics drug design platform company focused on autoimmune diseases that successfully completed an IPO prior to its acquisition by Merck for
"Rahul's experience as a successful entrepreneur and leader in the biotech industry and his expertise in drug R&D and biotechnology platforms will be invaluable to Quotient," said Noubar Afeyan, Ph.D., Co-founder of Quotient Therapeutics and Founder and CEO of Flagship Pioneering. "We're pleased to have him join as a CEO-Partner at Flagship and look forward to his contributions to Quotient, to Flagship, and to our ecosystem."
Jake Rubens, Ph.D., who co-founded and led Quotient as CEO, will stay involved in the company's growth as a board director. Under Rubens's leadership, Quotient pioneered the world's first industrial platform for the discovery of novel, human-validated drug targets via somatic genomics, validated and began drug discovery against the company's first targets across multiple diseases and therapeutic areas, established Quotient's research sites in the
"On behalf of the board, I am grateful to Jake for taking Quotient from concept to creation and know that he will continue to drive innovation of the platform from his role on the board," said Geoffrey von Maltzahn, Ph.D., Co-founder and Chairman of Quotient and General Partner at Flagship. "Rahul is a dynamic leader who has repeatedly cultivated valuable pipelines and scaled companies working at the frontiers of new domains of drug development. I look forward to working with him as we take the next big leap with Quotient."
Dr. Kakkar stated, "The Human Genome Project opened incredible avenues twenty years ago for therapeutics development, creating hundreds of new medicines for patients. Somatic genomics represents a similarly transformative step change, both in our understanding of disease biology and our ability as drug developers to create interventions. Quotient's platform reveals a wealth of novel drug targets encoded in the somatic genome and holds enormous potential to fuel the creation of first-in-class medicines that protect against, fight, or counter a broad range of diseases. I look forward to leading the company as we advance Quotient's pipeline and further realize the promise of its platform technology."
Rubens, who is also an Origination Partner at Flagship, added, "Rahul is ideally suited to lead Quotient toward our next horizons, growing and developing our platform and portfolio of target discoveries and medicines, and directing the company to the most attractive value creation opportunities."
About Quotient Therapeutics
Quotient Therapeutics is the first company to systematically study the genetic variation and evolution of the trillions of cells inside the human body. The company's Somatic Genomics platform reveals novel links between genes and disease across a broad range of therapeutic areas, enabling the discovery of transformative medicines intended to cure, prevent, or reverse disease. Founded by Flagship Pioneering in 2022, Quotient is backed by experts in the field of somatic genetics.
About Flagship Pioneering
Flagship Pioneering invents and builds bioplatform companies, each with the potential for multiple products that transform human health or sustainability. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, resulting in more than
Media Contacts:
View original content to download multimedia:https://www.prnewswire.com/news-releases/flagship-pioneering-appoints-rahul-kakkar-as-ceo-partner-and-ceo-of-quotient-therapeutics-302440596.html
SOURCE Flagship Pioneering
FAQ
What experience does Rahul Kakkar bring to Quotient Therapeutics (FHTX) as new CEO?
How has Quotient Therapeutics (FHTX) performed under previous CEO Jake Rubens?
What is Quotient Therapeutics' (FHTX) main technology platform?
What strategic partnerships does Quotient Therapeutics (FHTX) currently have?
What is the relationship between Flagship Pioneering and Quotient Therapeutics (FHTX)?
